Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

17.94 +0.24 (+1.36%)
Streaming Delayed Price Updated: 3:51 PM EDT, Aug 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Oculis Holding AG - Ordinary shares

Oculis Upsized Loan Facility to Access up to CHF 100 million
From Oculis Holding AG
Via GlobeNewswire
Oculis Publishes Results of 2025 Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Oculis to Participate in Upcoming June Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis Publishes Invitation to the Annual General Meeting
From Oculis Holding AG
Via GlobeNewswire
Oculis Reports Q1 2025 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
Oculis to Present at Upcoming May Investor Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
From Oculis Holding AG
Via GlobeNewswire
Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award
From Oculis Holding AG
Via GlobeNewswire
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
From Oculis Holding AG
Via GlobeNewswire
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
From Oculis Holding AG
Via GlobeNewswire
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy
From Oculis Holding AG
Via GlobeNewswire
Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
From Oculis SA
Via GlobeNewswire
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare... 
Via Newsfile
Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
From Oculis SA
Via GlobeNewswire
Oculis to Participate and Present at Upcoming EuDES Meeting
From Oculis SA
Via GlobeNewswire
Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops
From Oculis SA
Via GlobeNewswire
Oculis Co-founders Selected as Finalists in European Inventor Award 2023
From Oculis SA
Via GlobeNewswire
Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs
From Oculis SA
Via GlobeNewswire
Oculis to Participate at Upcoming Investor Conferences
From Oculis SA
Via GlobeNewswire
Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones
From Oculis SA
Via GlobeNewswire
Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing
From Oculis SA
Via GlobeNewswire
Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial
From Oculis SA
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.